OBJECTIVES: To calculate age adjusted risks for multiple sclerosis in relatives of Flemish patients with multiple sclerosis. METHODS: Lifetime risks were calculated using the maximum likelihood approach. RESULTS: Vital information was obtained on 674 probands with multiple sclerosis in Flanders and a total of their 26225 first, second, and third degree relatives. Full medical information to allow documentation of multiple sclerosis status was available for 21351 (81.4%) relatives. The age adjusted risk for parents was 1.61 (SEM 0.35)%, for siblings 2.10 (SE 0.36)%, and for children 1.71 (SEM 0.70)%. For aunts and uncles, the risk was 0.66 (SEM 0.13)%. CONCLUSIONS: The risk for first degree relatives of patients with multiple sclerosis in Flanders is increased 10-fold to 12-fold; for second degree relatives, it is increased threefold. This information can be used for risk counselling in families and provides additional support for the role of more than one locus contributing to the susceptibility of multiple sclerosis.
OBJECTIVES: To calculate age adjusted risks for multiple sclerosis in relatives of Flemish patients with multiple sclerosis. METHODS: Lifetime risks were calculated using the maximum likelihood approach. RESULTS: Vital information was obtained on 674 probands with multiple sclerosis in Flanders and a total of their 26225 first, second, and third degree relatives. Full medical information to allow documentation of multiple sclerosis status was available for 21351 (81.4%) relatives. The age adjusted risk for parents was 1.61 (SEM 0.35)%, for siblings 2.10 (SE 0.36)%, and for children 1.71 (SEM 0.70)%. For aunts and uncles, the risk was 0.66 (SEM 0.13)%. CONCLUSIONS: The risk for first degree relatives of patients with multiple sclerosis in Flanders is increased 10-fold to 12-fold; for second degree relatives, it is increased threefold. This information can be used for risk counselling in families and provides additional support for the role of more than one locus contributing to the susceptibility of multiple sclerosis.
Authors: G C Ebers; D E Bulman; A D Sadovnick; D W Paty; S Warren; W Hader; T J Murray; T P Seland; P Duquette; T Grey Journal: N Engl J Med Date: 1986-12-25 Impact factor: 91.245
Authors: C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte Journal: Ann Neurol Date: 1983-03 Impact factor: 10.422
Authors: Stephen Sawcer; Maria Ban; Mel Maranian; Tai Wai Yeo; Alastair Compston; Andrew Kirby; Mark J Daly; Philip L De Jager; Emily Walsh; Eric S Lander; John D Rioux; David A Hafler; Adrian Ivinson; Jacqueline Rimmler; Simon G Gregory; Silke Schmidt; Margaret A Pericak-Vance; Eva Akesson; Jan Hillert; Pameli Datta; Annette Oturai; Lars P Ryder; Hanne F Harbo; Anne Spurkland; Kjell-Morten Myhr; Mikko Laaksonen; David Booth; Robert Heard; Graeme Stewart; Robin Lincoln; Lisa F Barcellos; Stephen L Hauser; Jorge R Oksenberg; Shannon J Kenealy; Jonathan L Haines Journal: Am J Hum Genet Date: 2005-07-29 Impact factor: 11.025
Authors: Qunmin Zhou; Kottil Rammohan; Shili Lin; Nikki Robinson; Ou Li; Xingluo Liu; Xue-feng Bai; Lijie Yin; Bruce Scarberry; Peishuang Du; Ming You; Kunliang Guan; Pan Zheng; Yang Liu Journal: Proc Natl Acad Sci U S A Date: 2003-12-01 Impact factor: 11.205